| Name | Title | Contact Details |
|---|---|---|
Deron Means |
Sr. Director Information Security and Compliance | Profile |
Dungarvin is a national organization of privately owned companies that are dedicated to providing high quality, community-based supports to people with varying support needs. Founded in St. Paul, Minnesota in 1976, Dungarvin has grown to employ approximately 3,500 people who currently provide supports to over 3,200 individuals across 13 states. We believe all persons faced with the challenges of a disability have the same rights and the same basic needs as do other citizens without disabilities. Dungarvin`s mission and values apply to every person we serve, including those with significant behavioral, medical and physical challenges. We are committed to principles of self-determination, self-actualization, and to the preservation of dignity of each person we serve, regardless of the nature or degree of their needs. Dungarvin`s mission is respecting and responding to the choices of people in need of supports. Dungarvin provides a variety of individually tailored services and supports including supported living, day services, supported employment, case management, supported foster care, children`s services, respite care, elder care, host homes and supports for persons with traumatic brain injury and mental health needs in several states.
Mid Life Marketing is a Littleton, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
"Eleven uses its proprietary technology platform to create first-of-a-kind protein therapeutics to address unmet needs for ophthalmic diseases. Proteins are able to modulate inflammatory cytokines, key targets in ocular disease that have been difficult to access with conventional therapeutic approaches. A significant untapped opportunity exists for protein therapeutics to address ophthalmic diseases, and Eleven is applying its advanced protein technology and expertise to develop innovative medicines for patients suffering from ocular diseases. Eleven`s team of industry veterans has deep experience in understanding protein science and biologic drug development, designing and conducting clinical trials and, most importantly, applying specific expertise in ophthalmic disease to create novel ocular therapeutics to treat unmet medical needs. Eleven has developed a proprietary pipeline of ophthalmic drug candidates derived from the company`s innovative AMP-Rx protein engineering technology. The company`s initial product candidates are focused on targeting inflammatory cytokines and key targets of ocular disease by blocking the cytokines and modulating the biological processes that drive ocular disease. Current pipeline opportunities include ocular surface diseases such as dry eye disease (DED) and allergic conjunctivitis (AC), and back of the eye diseases such as diabetic macular edema (DME) and uveitis. In addition, Eleven’s proprietary technology has been utilized to prolong the intravitreal half-life of our pipeline products. Beyond its internal drug development programs, Eleven works with collaborators, such as ThromboGenics, to apply its innovative protein therapeutic design capabilities to engineer and develop biotherapeutic products for additional therapeutic targets. EBI-005, Eleven`s lead product candidate, is a novel interleukin-1 (IL-1) receptor antagonist in Phase 3 clinical development as one of the first topically administered proteins for the treatment of DED and AC, two inflammatory diseases at the surface of the eye."
Agili-T Health Solutions is a Varennes, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
LeMaitre Vascular, Inc. (LeMaitre Vascular) is a provider of medical devices and implants for the treatment of peripheral vascular disease. The Company develops, manufactures, and markets vascular devices.